Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Jun;25(6):1002–1008. doi: 10.1128/jcm.25.6.1002-1008.1987

Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32).

H K Webster, E F Boudreau, L W Pang, B Permpanich, P Sookto, R A Wirtz
PMCID: PMC269124  PMID: 2439533

Abstract

Antibodies that reacted with a candidate sporozoite vaccine antigen (R32tet32) were found in 20 of 21 patients treated for acute infection with Plasmodium falciparum and monitored longitudinally over 67 days. R32tet32 contains 32 tandem copies of a tetrapeptide sequence that constitutes the immunodominant epitope of the circumsporozoite surface protein. The magnitude of the antibody response varied considerably among individuals and appeared to be independent of the number of previous clinical infections. Recrudescence of infection or infection with Plasmodium vivax had no demonstrable effect on antibody levels, although reinfection with P. falciparum produced a rapid rise in antibody titer. Antibody levels were observed to decline rapidly after treatment of clinical infection with mefloquine. The apparent antibody half-life was 27 days, which is comparable to the half-life of circulating immunoglobulin G in humans. The data suggest that antisporozoite antibody production ceased on about day 4 after treatment of acute infection. A similar pattern of response was observed for antibodies against the erythrocytic forms of the parasite. The cessation of antibody synthesis was interpreted as being due to immunosuppression induced by the presence of intraerythrocytic parasites and may explain in part why protective immunity is poorly developed in natural malaria infections.

Full text

PDF
1002

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballou W. R., Rothbard J., Wirtz R. A., Gordon D. M., Williams J. S., Gore R. W., Schneider I., Hollingdale M. R., Beaudoin R. L., Maloy W. L. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science. 1985 May 24;228(4702):996–999. doi: 10.1126/science.2988126. [DOI] [PubMed] [Google Scholar]
  2. COLLINS W. E., JEFFERY G. M., SKINNER J. C. FLUORESCENT ANTIBODY STUDIES IN HUMAN MALARIA. II. DEVELOPMENT AND PERSISTENCE OF ANTIBODIES TO PLASMODIUM FALCIPARUM. Am J Trop Med Hyg. 1964 Mar;13:256–260. doi: 10.4269/ajtmh.1964.13.256. [DOI] [PubMed] [Google Scholar]
  3. Clyde D. F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975 May;24(3):397–401. doi: 10.4269/ajtmh.1975.24.397. [DOI] [PubMed] [Google Scholar]
  4. Clyde D. F., Most H., McCarthy V. C., Vanderberg J. P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973 Sep;266(3):169–177. doi: 10.1097/00000441-197309000-00002. [DOI] [PubMed] [Google Scholar]
  5. Dame J. B., Williams J. L., McCutchan T. F., Weber J. L., Wirtz R. A., Hockmeyer W. T., Maloy W. L., Haynes J. D., Schneider I., Roberts D. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984 Aug 10;225(4662):593–599. doi: 10.1126/science.6204383. [DOI] [PubMed] [Google Scholar]
  6. Druilhe P., Pradier O., Marc J. P., Miltgen F., Mazier D., Parent G. Levels of antibodies to Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are persistent in the absence of reinfection. Infect Immun. 1986 Aug;53(2):393–397. doi: 10.1128/iai.53.2.393-397.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Godson G. N., Ellis J., Svec P., Schlesinger D. H., Nussenzweig V. Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein. Nature. 1983 Sep 1;305(5929):29–33. doi: 10.1038/305029a0. [DOI] [PubMed] [Google Scholar]
  8. Ho M., Webster H. K., Looareesuwan S., Supanaranond W., Phillips R. E., Chanthavanich P., Warrell D. A. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J Infect Dis. 1986 Apr;153(4):763–771. doi: 10.1093/infdis/153.4.763. [DOI] [PubMed] [Google Scholar]
  9. Hoffman S. L., Wistar R., Jr, Ballou W. R., Hollingdale M. R., Wirtz R. A., Schneider I., Marwoto H. A., Hockmeyer W. T. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med. 1986 Sep 4;315(10):601–606. doi: 10.1056/NEJM198609043151001. [DOI] [PubMed] [Google Scholar]
  10. Hollingdale M. R., Nardin E. H., Tharavanij S., Schwartz A. L., Nussenzweig R. S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984 Feb;132(2):909–913. [PubMed] [Google Scholar]
  11. Mathews H. M., Dondero T. J., Jr A longitudinal study of malaria antibodies in a Malaysian population. I. Group responses. Am J Trop Med Hyg. 1982 Jan;31(1):14–18. doi: 10.4269/ajtmh.1982.31.14. [DOI] [PubMed] [Google Scholar]
  12. Nardin E. H., Nussenzweig R. S., McGregor I. A., Bryan J. H. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science. 1979 Nov 2;206(4418):597–599. doi: 10.1126/science.386511. [DOI] [PubMed] [Google Scholar]
  13. Nardin E. H., Nussenzweig V., Nussenzweig R. S., Collins W. E., Harinasuta K. T., Tapchaisri P., Chomcharn Y. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med. 1982 Jul 1;156(1):20–30. doi: 10.1084/jem.156.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nussenzweig R. S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967 Oct 14;216(5111):160–162. doi: 10.1038/216160a0. [DOI] [PubMed] [Google Scholar]
  15. Nussenzweig R. Use of radiation-attenuated sporozoites in the immunoprophylaxis of malaria. Int J Nucl Med Biol. 1980;7(2):89–96. doi: 10.1016/0047-0740(80)90026-1. [DOI] [PubMed] [Google Scholar]
  16. Orjih A. U. Acute malaria prolongs susceptibility of mice to Plasmodium berghei sporozoite infection. Clin Exp Immunol. 1985 Jul;61(1):67–71. [PMC free article] [PubMed] [Google Scholar]
  17. Potocnjak P., Yoshida N., Nussenzweig R. S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med. 1980 Jun 1;151(6):1504–1513. doi: 10.1084/jem.151.6.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tapchaisri P., Asavanich A., Limsuwan S., Tharavanij S., Harinasuta K. T. Antibodies against malaria sporozoites in patients with acute uncomplicated malaria and patients with cerebral malaria. Am J Trop Med Hyg. 1985 Sep;34(5):831–836. doi: 10.4269/ajtmh.1985.34.831. [DOI] [PubMed] [Google Scholar]
  19. Tapchaisri P., Chomcharn Y., Poonthong C., Asavanich A., Limsuwan S., Maleevan O., Tharavanij S., Harinasuta T. Anti-sporozoite antibodies induced by natural infection. Am J Trop Med Hyg. 1983 Nov;32(6):1203–1208. doi: 10.4269/ajtmh.1983.32.1203. [DOI] [PubMed] [Google Scholar]
  20. Thong Y. H., Ferrante A., Rowan-Kelly B., O'Keefe D. E. Effect of mefloquine on the immune response in mice. Trans R Soc Trop Med Hyg. 1979;73(4):388–390. doi: 10.1016/0035-9203(79)90160-3. [DOI] [PubMed] [Google Scholar]
  21. Thong Y. H., Ferrante A., Secker L. K. Normal immunological responses in mice treated with chloroquine, quinine and primaquine. Trans R Soc Trop Med Hyg. 1981;75(1):108–109. doi: 10.1016/0035-9203(81)90021-3. [DOI] [PubMed] [Google Scholar]
  22. Voller A., O'Neill P. Immunofluorescence method suitable for large-scale application to malaria. Bull World Health Organ. 1971;45(4):524–529. [PMC free article] [PubMed] [Google Scholar]
  23. Waldmann T. A. Disorders of immunoglobulin metabolism. N Engl J Med. 1969 Nov 20;281(21):1170–1177. doi: 10.1056/NEJM196911202812107. [DOI] [PubMed] [Google Scholar]
  24. Williamson W. A., Greenwood B. M. Impairment of the immune response to vaccination after acute malaria. Lancet. 1978 Jun 24;1(8078):1328–1329. doi: 10.1016/s0140-6736(78)92403-0. [DOI] [PubMed] [Google Scholar]
  25. Young J. F., Hockmeyer W. T., Gross M., Ballou W. R., Wirtz R. A., Trosper J. H., Beaudoin R. L., Hollingdale M. R., Miller L. H., Diggs C. L. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science. 1985 May 24;228(4702):958–962. doi: 10.1126/science.2988125. [DOI] [PubMed] [Google Scholar]
  26. Zavala F., Cochrane A. H., Nardin E. H., Nussenzweig R. S., Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med. 1983 Jun 1;157(6):1947–1957. doi: 10.1084/jem.157.6.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zavala F., Tam J. P., Hollingdale M. R., Cochrane A. H., Quakyi I., Nussenzweig R. S., Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985 Jun 21;228(4706):1436–1440. doi: 10.1126/science.2409595. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES